12:00 AM
 | 
Nov 18, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

PAZ320: Phase IIb started

Boston Therapeutics began a double-blind, placebo-controlled, French Phase IIb trial to evaluate PAZ320 in 24 Type II diabetics being...

Read the full 74 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >